NCT03762369

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Multi Center, Randomized, Double-blind, Active Controlled, Parallel Design, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-351 in Primary Open Angle Glaucoma or Ocular Hypertension Patients

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 384 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate efficacy and safety of CKD-351.

Detailed description

Multi center, Randomized, Double-blind, Active controlled, Parallel design, Phase 3 trial to evaluate the efficacy and safety of CKD-351 in primary open angle glaucoma or ocular hypertension patients.

Conditions

• Primary Open-angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	CKD-351	twice a day
DRUG	Latanoprost	once a day
DRUG	D930	three times a day
DRUG	Placebo of CKD-351	once a day
DRUG	Placebo of CKD-351	twice a day
DRUG	Placebo of D930	three times a day

Timeline

• Start date: 2018-12-07
• Primary completion: 2022-02-28
• Completion: 2022-05-30
• First posted: 2018-12-03
• Last updated: 2018-12-03

Locations

1 site across 1 country: South Korea